This video shows the right eye of a sickle cell disease patient with HbSS genotype and non-proliferative sickle cell retinopathy, at baseline (left panel) and two months (right panel) following initiation of oral hydroxyurea treatment. See J. I. W. Morgan et al. Biomedical Optics Express 14, 387-428 (2023).